Advertisement
AURA vs EVGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Hold and EVGN is a Hold.
AURA's Stochastic Oscillator stoops into oversold zone
The Stochastic Oscillator for AURA moved into oversold territory on October 16, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AURA's RSI Indicator exited the oversold zone, 15 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on AURA as a result. In 82 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for AURA just turned positive on October 06, 2026. Looking at past instances where AURA's MACD turned positive, the stock continued to rise in 44 of 54 cases over the following month. The odds of a continued upward trend are 81%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where AURA advanced for three days, in 215 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day moving average for AURA crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for AURA entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.007) is normal, around the industry mean (2.835). P/E Ratio (-3.526) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. AURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EVGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 24, 2026
EVGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 45 cases where EVGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVGN's RSI Oscillator exited the oversold zone, 36 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for EVGN just turned positive on October 15, 2026. Looking at past instances where EVGN's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVGN advanced for three days, in 142 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVGN as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EVGN entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.855) is normal, around the industry mean (2.835). P/E Ratio (-0.522) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (3.012) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. EVGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EVGN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | |
P/E GROWTH RATING 1..100 | 31 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AURA | EVGN | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 71% | 4 days ago 84% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 82% |
| Momentum ODDS (%) | 4 days ago 74% | 4 days ago 88% |
| MACD ODDS (%) | 4 days ago 81% | 4 days ago 79% |
| TrendWeek ODDS (%) | 4 days ago 84% | 4 days ago 75% |
| TrendMonth ODDS (%) | 4 days ago 85% | 4 days ago 90% |
| Advances ODDS (%) | 11 days ago 78% | 7 days ago 72% |
| Declines ODDS (%) | 6 days ago 83% | 11 days ago 90% |
| BollingerBands ODDS (%) | N/A | 4 days ago 84% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AURA’s FA Score shows that 1 FA rating(s) are green while EVGN’s FA Score has 2 green FA rating(s).
- AURA’s FA Score: 1 green, 4 red.
- EVGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AURA’s TA Score shows that 5 TA indicator(s) are bullish while EVGN’s TA Score has 5 bullish TA indicator(s).
- AURA’s TA Score: 5 bullish, 3 bearish.
- EVGN’s TA Score: 5 bullish, 3 bearish.
Price Growth
AURA (@Biotechnology) experienced а -6.73% price change this week, while EVGN (@Biotechnology) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
AURA is expected to report earnings on Nov 05, 2026.
EVGN is expected to report earnings on Nov 18, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AURA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AURA has been loosely correlated with MLTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then MLTX could also see price increases.
| Ticker / NAME | Correlation To AURA | 1D Price Change % | ||
|---|---|---|---|---|
| AURA | 100% | -3.79% | ||
| MLTX - AURA | 44% Loosely correlated | -6.92% | ||
| MGTX - AURA | 43% Loosely correlated | -6.17% | ||
| EDIT - AURA | 43% Loosely correlated | -3.69% | ||
| RCUS - AURA | 42% Loosely correlated | -3.07% | ||
| CABA - AURA | 42% Loosely correlated | -9.03% | ||
More | ||||
EVGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVGN has been loosely correlated with NCNA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EVGN jumps, then NCNA could also see price increases.
| Ticker / NAME | Correlation To EVGN | 1D Price Change % | ||
|---|---|---|---|---|
| EVGN | 100% | -3.01% | ||
| NCNA - EVGN | 43% Loosely correlated | -2.93% | ||
| INSM - EVGN | 30% Poorly correlated | -2.96% | ||
| AXON - EVGN | 30% Poorly correlated | -6.45% | ||
| AURA - EVGN | 28% Poorly correlated | -3.79% | ||
| ARRY - EVGN | 28% Poorly correlated | -3.92% | ||
More | ||||